ADVA Biotechnology

Automated Platform for Autologous Cell Manufacturing

Health Tech & Life Sciences
Active
Seed פארק תעשיות בר-לב, Israel Founded 2016
Last updated 2026-06-18
Total raised
$385K
Last: Grant 2024-09
Stage
Seed
Founded
2016
Headcount
23
HQ
פארק תעשיות בר-לב, Israel
Sector
Health Tech & Life Sciences

About

ADVA Biotechnology develops enabling technologies for cell therapy manufacturing. The company has developed ADVA X3, a robust, modular cell-manufacturing cGMP system based on a single-use end-to-end solution. ADVA X3 enables autologous cell therapy manufacturing at the bedside, allowing optimization, tight quality assurance, improved availability, reduced time to market, and significant cost reduction. The automated platform is designed to enable autologous manufacturing of additional types of cells with a change in the disposable chamber, allowing efficiency and flexibility with a long pipeline of products.

Funding history · 3 rounds · $385K total

2024-09
2021-06
Undisclosed
2020-08
Undisclosed

Q&A

What is ADVA Biotechnology's primary focus?
ADVA Biotechnology develops enabling technologies for cell therapy manufacturing, specifically an automated platform for autologous cell manufacturing called ADVA X3.
When was ADVA Biotechnology founded?
ADVA Biotechnology was founded in September 2016.
How many employees does ADVA Biotechnology have?
ADVA Biotechnology has 11-50 employees.
What is the total amount of funding ADVA Biotechnology has raised to date?
ADVA Biotechnology has raised a total of $385,000.
Which investors participated in ADVA Biotechnology's funding rounds?
ADVA Biotechnology has received funding from ExitValley, AGP Ventures, and the Israel Innovation Authority.
When did ADVA Biotechnology receive its most recent funding?
ADVA Biotechnology received a Grant round in September 2024, amounting to $385,000, from the Israel Innovation Authority.
Who are the founders of ADVA Biotechnology?
The founders of ADVA Biotechnology are Ohad Karnieli, Tal Slonim, Ron Elazary-Vulcani, and Barbara Paldus.
What is the main product developed by ADVA Biotechnology?
ADVA Biotechnology has developed ADVA X3, a robust, modular cell-manufacturing cGMP system based on a single-use end-to-end solution for autologous cell therapy manufacturing.

Team · 4

Founder · Co-founder & Board Member
LinkedIn ↗
Founder · Co-founder & Board Member
Founder · Co-founder & Board Member
LinkedIn ↗
Founder · Founder & CEO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticals
Business model
B2B

Tags

medical-technologiespatientsbiotechnologymedical-deviceshospitalscancercell-therapyimmunologymanufacturinggenetic-engineeringautomationmonitoring
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)